Skip to content
  • Listed
  • Biotechnology — Full Life Cycle

RTW Biotech Opportunities Ltd (“RTW”) appointed Cadarn Capital in May 2023 to provide distribution and investor relations services.

RTW Biotech Opportunities Ltd. is an investment fund focused on identifying transformative assets with growth potential across the life sciences sector. The Fund’s approach is driven by applying deep scientific expertise with a long-term investment horizon.

RTW believe the companies best positioned to overcome these near-term challenges will be those who have chosen to focus on therapies for severe diseases with limited options and that also have meaningful commercial potential.  

Share
Fund Structures

Listed funds are investment vehicles traded on regulated exchanges, offering investors daily liquidity, transparent pricing, and ease of access. They are typically subject to exchange rules and ongoing disclosure requirements, making them suitable for a broad range of investors.

UCITS funds (Undertakings for Collective Investment in Transferable Securities) are a type of highly regulated investment fund in the European Union (EU) designed for retail investors.

Alternative investment funds provide access to assets such as private credit, infrastructure, or real assets, with limited or periodic liquidity. These funds are designed for longer-term strategies, offering diversification benefits beyond traditional listed markets.

Investor Portal

Exclusive access for professional investors

The Investor Portal provides professional investors with exclusive access to upcoming Cadarn events, detailed fund portfolio insights and associated fund materials. A dedicated information hub that offers an insight into our fund partners’ respective investment approaches, market insights and fund news.

Sign up

Cadarn Capital Ltd (FRN: 998015) is an appointed representative of Thornbridge Investment Management LLP (FRN: 713859) which is authorised and regulated by the Financial Conduct Authority